On December 10, 2025, ZonhonBio initiated the Phase I clinical trial of ZHB117 Sublingual Tablets—an independently developed Class 1 novel biologic therapy with proprietary intellectual property rights both domestically and internationally—at Beijing Tongren Hospital, Capital Medical University.

As the sponsor, ZonhonBio launched the study titled “A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of ZHB117 Sublingual Tablets in Adult Subjects with Cat Allergen-Induced Allergic Rhinitis or Rhinoconjunctivitis (With or Without Allergic Asthma).” The trial is led by Principal Investigator Professor Zhang Luo, President of Capital Medical University and Director of Beijing Tongren Hospital, who will oversee the assessment of the safety and tolerability of ZHB117 Sublingual Tablets in enrolled subjects following administration.

Allergen-specific immunotherapy, also known as desensitization therapy, is currently recognized as the only treatment approach capable of potentially altering the natural course of allergic diseases. ZHB117 is a novel sublingual desensitization vaccine formulation characterized by controllable dosing, excellent storage stability, and convenient administration. By delivering the therapy sublingually, ZHB118 induces immune tolerance, thereby modifying the progression of allergic conditions and providing sustained symptom relief. This innovative therapy offers a new treatment solution for patients with cat allergies and aims to improve their quality of life.